期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雷替曲塞联合重组改构人肿瘤坏死因子(TNF-α)治疗腹膜假黏液瘤1例 被引量：2

原文传递
导出
摘要 腹膜假黏液瘤（pseudomyxoma peritonei PMP）是一种主要来源于阑尾的上皮性肿瘤,以播散性腹膜黏液性肿瘤的沉积和进行性黏液性腹水为特征的临床疾病,常因巨大肿瘤或大量腹水导致肠梗阻、营养不良、多器官功能衰竭而死亡。本病临床少见,且治疗效果欠佳,现报告1例我们治疗成功的PM P案例,旨在探讨此病新的治疗方法,为后续研究提供病例依据。
作者 姜明静 高扬 邹磊 管杰
机构地区 济南大学山东省医学科学院医学与生命科学学院 山东省肿瘤医院外科四病区
出处 《山东大学学报（医学版）》 CAS 北大核心 2016年第7期93-96,共4页 Journal of Shandong University:Health Sciences
关键词 腹膜假黏液瘤 雷替曲塞 肿瘤坏死因子
分类号 R572.2 [医药卫生—消化系统]
  • 相关文献

参考文献12

  • 1McDonald JR, O'Dwyer ST, Renehan AG, et al. Classi- fication of and cytoreductive surgery for lowgrade appen- diceal mucinous neoplasms [J ]. Br J Surg, 2012, 99 ( 7 ) : 987-992.
  • 2Renehan AG, O' Dwyer ST, Stern PL. Pseudomyxoma peritonei[ M] //. In: Schwab M, ed. Encyclopedia of Cancer. ( London: Springer) , 2008 : 2134-2138.
  • 3Roberts DL, O'Dwyer ST, Stern PL, et al. Global gene expression in pseudomyxoma peritonei, with parallel de- velopment of two immortalized cell lines[J]. Oncotarget, 2015, 6(13) : 10786-10800.
  • 4Joo MW, Chung YG, Hur SY, et al. Pseudomyxoma peritonei extending to the lower extremity: a case report [J]. World J SurgOncol, 2015, 13:221. doi: 10.1186/ s12957-015-0639-x.
  • 5Smeenk RM, Verwaal VJ, Antonini N, et al. Progression of pseudomyxoma peritonei after combined modality treat- ment: management and outcome [ J ]. Ann Surg Oncol, 2007, 14(2) : 493499.
  • 6Chua TC, Liauw W, Morris DL. Early recurrence of pseudomyxoma peritonei following treatment failure of cy- toreductive surgery and perioperative intraperitoneal chem- otherapy is indicative of a poor survival outcome[ J]. lntJ Colorectal Dis, 2012, 27(3) : 381-389.
  • 7Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei [J]. Ann Surg Oncol, 2007, 14(2) : 484-492.
  • 8Chen YN, Lee J J, Cheng SP, et al. Transformation of low-grade mucinous neoplasm of the appendix with pseud- omyxoma peritonei to high-grade sarcomatoid carcinoma[J]. J Clin Med Res, 2015, 7(7) : 571-574.
  • 9Kulu Y, Miiller-Stich B, Biichler MW, et al. Surgical treatment of peritoneal carcinomatosis: current treatment modalities[J]. Langenbecks Arch Surg, 2014, 399( 1 ) :41-53.
  • 10吴婷婷,陈丁丁,智俊娜,陆建伟.雷替曲塞的临床应用[J].中国现代应用药学,2014,31(5):643-646. 被引量：16

二级参考文献66

  • 1孙宇,钟武,李松.肿瘤坏死因子转化酶(TACE)抑制剂的研究进展[J].中国药物化学杂志,2006,16(3):188-192. 被引量：2
  • 2CHOY E H S, PANAYI G S N. Cytokine pathways and joint inflammation in rheumatoid arthritis [ J ]. N Engl J Med,2001, (344) :907 -916.
  • 3GARRISON L, MCDONNELL N D. Etanercept: therapeutic use in patients with rheumatoid arthritis [J]. Ann Rheum Dis, 1999,58 ( Suppl. 1 ) : 165 - 169.
  • 4NELSON F C, SANTOS E D. Benzodiazepine inhibitors of the MMPs and TACE[ J].Bioorg Med Chem Lett,2002,12 (20) :2867 - 2877.
  • 5ELLIOTT S ,CAWSTON T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders [ J]. Drugs Aging,2001,18 (2) :87 - 99.
  • 6SHAW T S, NIXON J S, BOTTOMLEY K M. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis [J]. Exp Opin Invest Drugs,2000,9 (7) : 1469 - 1478.
  • 7AGGARWAL B B, KOHR W J, HASS P E, et al. Human tumor necrosis factor. Production, purification, and characterization [ J ]. Biol Chem, 1985,260 (4) :2345 - 2354.
  • 8TRACEY K J, CERAMI A. Tumour necrosis factor: a pleiotropic cytokine and therapeutic target[ J]. Annu Rev Med, 1994,45:491 -503.
  • 9AGGARWAL B B, NATARAJAN K. Tumor necrosis factors: developments during the last decade. [ J ]. Euro Cytokine Netw, 1996,7 (2) :93 -124.
  • 10BEMELMANS M H A,VAN TITS L J H,BUURMAN W A. Tumor necrosis factor: function, release and clearance [ J ]. Crit Rev Immunol, 1996,16 ( 1 ) : 1 -11.

共引文献24

同被引文献14

引证文献2

二级引证文献2

山东大学学报（医学版）
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部